相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Raymond Y. Huang et al.
CLINICAL CANCER RESEARCH (2016)
Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans
Nathalie L. Albert et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab
Robert J. Harris et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM
Bogdana Suchorska et al.
NEUROLOGY (2015)
Prognostic Significance of Dynamic 18F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma
Nathalie L. Jansen et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
Johannes Schwarzenberg et al.
CLINICAL CANCER RESEARCH (2014)
PET imaging for brain tumor diagnostics
Bogdana Suchorska et al.
CURRENT OPINION IN NEUROLOGY (2014)
Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option
Maya Flieger et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
Maximilian Niyazi et al.
RADIATION ONCOLOGY (2014)
Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy
Kazuhiro Miwa et al.
RADIATION ONCOLOGY (2014)
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
Brian J. Gebhardt et al.
RADIATION ONCOLOGY (2014)
Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab
Kevin Leu et al.
CANCER IMAGING (2014)
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations
Christian Hartmann et al.
CLINICAL CANCER RESEARCH (2013)
Response assessment of bevacizumab in patients with recurrent malignant glioma using [F-18]Fluoroethyl-l-tyrosine PET in comparison to MRI
Norbert Galldiks et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
Thomas Hundsberger et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma
Markus Hutterer et al.
NEURO-ONCOLOGY (2013)
MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?
Nathalie L. Jansen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
IRRADIATION AND BEVACIZUMAB IN HIGH-GRADE GLIOMA RETREATMENT SETTINGS
Maximilian Niyazi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET
Maximilian Niyazi et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
3 '-Deoxy-3 '-F-18-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab
Johannes Schwarzenberg et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab
Robert J. Harris et al.
NEURO-ONCOLOGY (2012)
Genetic profile of astrocytic and oligodendroglial gliomas
Hiroko Ohgaki et al.
BRAIN TUMOR PATHOLOGY (2011)
O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma
Markus Hutterer et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
FET-PET for malignant glioma treatment planning
Maximilian Niyazi et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy
Marc D. Piroth et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Therapeutic options for recurrent malignant glioma
Maximilian Niyazi et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Early metabolic responses in temozolomide treated low-grade glioma patients
Matthias Wyss et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison
Marc D. Piroth et al.
RADIATION ONCOLOGY (2009)
The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment
J. H. Mehrkens et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
